AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Suganril-SL Tablet

Prescription Icon
Prescription Required

Marketer

Abbott

Salt Composition

Piroxicam (20mg)

Overview Suganril-SL Tablet

ArthroEase tablets provide effective pain relief. This medication targets moderate to severe pain associated with conditions like osteoarthritis and rheumatoid arthritis, easing joint and muscle pain and inflammation. It's also sometimes prescribed post-dental procedures. ArthroEase should be taken with food to minimize stomach upset. Dosage and treatment length vary depending on the condition and response; follow your doctor's instructions precisely for optimal results. Exceeding the prescribed dose or duration can be harmful. Common side effects include mild nausea, vomiting, indigestion, stomach pain, and diarrhea. Persistent or worsening side effects require immediate medical attention; your doctor may offer solutions to alleviate these symptoms. Before starting ArthroEase, inform your physician of any pre-existing conditions, including stomach ulcers, heart problems, high blood pressure, liver or kidney disease. Always disclose all other medications you're taking, as interactions are possible. Pregnant or breastfeeding individuals must consult their doctor before use.

Uses of Suganril-SL Tablet

Alleviation of discomfort

Major Benefits of Suganril-SL Tablet:

Allow the tablet to dissolve by positioning it either beneath your tongue or nestled against your gum. Avoid chewing, crushing, or ingesting the tablet whole. Suganril-SL should be administered with a meal.

Common Side effects of Suganril-SL Tablet:

  • Vomiting
  • Stomach pain
  • Nausea
  • Headache
  • Dizziness

How to use Suganril-SL Tablet:

Allow the tablet to dissolve completely by positioning it either sublingually or buccally. Avoid chewing, crushing, or swallowing the tablet whole. Suganril-SL should be administered with a meal.

How Suganril-SL Tablet works:

Suganril-SL tablets contain a non-steroidal anti-inflammatory agent that inhibits the production of inflammatory mediators, thereby reducing pain and edema.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Suganril-SL Tablet with alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Suganril-SL Tablets during pregnancy may pose risks. While human research is scant, animal studies indicate potential harm to a developing fetus. A physician will assess the potential benefits against any risks prior to prescription. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Breastfeeding mothers should likely avoid Suganril-SL Tablets. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingUNSAFE

Taking Suganril-SL Tablets might reduce attentiveness, impair vision, or cause drowsiness and dizziness. Driving should be avoided if these effects are experienced.

KidneyKidneyCAUTION

Patients with severe renal impairment should exercise caution when using Suganril-SL Tablets; dosage modification may be necessary. Physician consultation is advised.

LiverLiverCAUTION

Patients with hepatic impairment should use Suganril-SL Tablets cautiously; dosage modification may be necessary. Physician consultation is advised.

What if you forget to take Suganril-SL Tablet :

Should you forget a Suganril-SL Tablet dose, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Suganril-SL Tablet

LabelValue
Type of Compound Compounds derived from enolic acids
Addictive None.
Type of Medication Medications for Pain Relief

FAQs on Suganril-SL Tablet

Suganril-SL Tablet and diclofenac are analgesics. Piroxicam, the active ingredient in Suganril-SL Tablet, is a non-selective cyclooxygenase (COX) inhibitor, an enzyme contributing to inflammation and pain. Diclofenac exhibits greater selectivity for the COX-2 enzyme. This enhanced selectivity in diclofenac is believed to reduce adverse effects relative to Suganril-SL Tablet.
Naproxen and Suganril-SL Tablet are analgesics, both non-selectively inhibiting COX enzymes, the source of inflammation and pain signaling. Clinical trials indicate comparable efficacy between the two. Nevertheless, naproxen exhibits a lower incidence of gastrointestinal adverse effects than Suganril-SL Tablet.
Suganril-SL Tablet and meloxicam are analgesics, both non-selectively inhibiting cyclooxygenase, the enzyme mediating inflammation and pain perception. Clinical trials demonstrate comparable efficacy between the two. Nevertheless, meloxicam exhibits a lower incidence of acute gastrointestinal adverse events relative to Suganril-SL Tablet.
Suganril-SL Tablet and ketoprofen are both analgesics, non-selectively inhibiting cyclooxygenase, the enzyme mediating inflammation and pain. Clinical trials indicate superior efficacy and effectiveness of topical ketoprofen gel versus Suganril-SL Tablet. Furthermore, the gel demonstrated excellent patient acceptance.
Suganril-SL tablets contain a COX inhibitor (cyclooxygenase, an enzyme contributing to inflammation and pain), while Tramadol acts as an opioid analgesic. Tramadol carries a risk of dependence.
Suganril-SL Tablet and nimesulide are analgesics. Suganril-SL Tablet, unlike nimesulide, non-selectively inhibits COX enzymes, which mediate inflammation and pain. Nimesulide's COX-2 selectivity aims to reduce adverse reactions relative to piroxicam. Its use is contraindicated in children under 12.
Chikungunya typically doesn't cause a decrease in platelet levels. However, analgesics such as piroxicam increase the risk of bleeding. Therefore, avoid Suganril-SL Tablet or other pain relievers if you experience fever with joint pain. Always seek medical advice before using Suganril-SL Tablet.
Suganril-SL Tablets and aspirin are distinct medications, although both are classified as COX (cyclooxygenase) inhibitors, sharing anti-inflammatory and analgesic properties.
Concurrent use of Suganril-SL tablets and dexamethasone is contraindicated due to their synergistic toxicity, significantly raising the likelihood of gastrointestinal ulceration.
Concurrent use of methocarbamol and Suganril-SL tablets is considered safe, lacking documented severe adverse interactions. However, physician consultation is advised prior to initiating either treatment.
Confirmation: Concurrent use of paracetamol and Suganril-SL Tablet is permissible, as no significant adverse reactions have been documented. Physician consultation is advised prior to commencing either treatment.
Affirmative. Suganril-SL Tablet belongs to the non-steroidal anti-inflammatory drug class.
Suganril-SL tablets contain sulfur. This medication may trigger serious side effects in susceptible patients, including severe dermatological reactions such as Stevens-Johnson syndrome. Always disclose any allergies to your physician.
Suganril-SL Tablets do not act as anticoagulants; they are analgesics. Their use is contraindicated in individuals with hemorrhagic conditions.
Suganril-SL Tablets do not relax muscles. This medication is an analgesic that targets COX enzymes (cyclooxygenase), which are involved in pain and inflammation.
Suganril-SL Tablets are not classified as narcotics. This analgesic medication targets the COX enzyme (cyclooxygenase), an enzyme that contributes to inflammation and pain, thus reducing both.
Suganril-SL Tablets do not manage high blood pressure. Concomitant use with antihypertensive drugs reduces their efficacy. Disclose current antihypertensive medication use to your physician prior to commencing Suganril-SL Tablet therapy.
Concurrent use of Suganril-SL Tablet and Losartan is contraindicated. Suganril-SL Tablet diminishes the efficacy of antihypertensive agents such as Losartan, potentially rendering antihypertensive treatment ineffective. Disclose any current antihypertensive medication use to your physician prior to commencing Suganril-SL Tablet therapy.
Suganril-SL Tablets and lisinopril should not be used concurrently. Concomitant use of piroxicam with lisinopril reduces the antihypertensive drug's efficacy, potentially resulting in treatment failure. Patients currently using antihypertensive drugs must disclose this to their physician prior to commencing Suganril-SL Tablet therapy.
Confirmed. Suganril-SL Tablets may be administered concurrently with calcium channel blockers. Studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) diminish the efficacy of most antihypertensive medications, with calcium channel blockers being a noted exception (White, 2007).
Suganril-SL Tablets may be used concurrently with tizanidine. Tizanidine, a skeletal muscle relaxant, complements piroxicam, an analgesic, in managing conditions such as back pain.
Affirmative. Suganril-SL Tablet's concurrent use with beta-cyclodextrin is feasible. Studies indicate this combination accelerates piroxicam's therapeutic effect and diminishes gastrointestinal adverse reactions.
Affirmative. Suganril-SL Tablet has substitute medications. Analgesic selection depends on the specific ailment. Physician consultation is advised prior to commencing piroxicam therapy or switching treatments.
Piroxicam should not be used by individuals with allergies to the drug, bleeding disorders, duodenal, gastric, or peptic ulcers, mouth sores (stomatitis), systemic lupus erythematosus (SLE), ulcerative colitis, upper gastrointestinal problems, late-stage pregnancy, heart conditions, liver dysfunction, or kidney dysfunction.
Suganril-SL Tablets do not alleviate allergic reactions; they are an analgesic.
Suganril-SL tablets provide extended pain relief with a single daily dose. However, individual responses vary, and the analgesic effects of piroxicam generally improve with continued use over several weeks.
Suganril-SL Tablets are not associated with hypertension; they are a non-opioid analgesic.
Suganril-SL tablets are not indicated for managing menstrual pain. Clinical trials have demonstrated that piroxicam is highly effective in substantially reducing menstrual cramp severity.
Suganril-SL tablets lack regulatory approval for migraine management. Clinical trials have demonstrated that Suganril-SL tablets effectively reduce migraine pain in patients without aura.
Affirmative. This medication may alleviate back pain. Nevertheless, a physician's consultation is necessary to determine the underlying cause of your back pain before initiating treatment. Avoid self-treating with Suganril-SL Tablets, as the etiology of back pain varies individually.
Affirmative. Suganril-SL Tablets are indicated for acute gout management. Clinical trials demonstrate significant efficacy of Suganril-SL Tablets in treating acute gout episodes.
Blood donation is permissible while taking Suganril-SL Tablets; however, it's crucial to disclose your medication use to the physician prior to donation.
In diabetic patients, the use of Suganril-SL tablets requires physician oversight due to the potential for prolonged use to induce kidney failure. Since diabetes is a pre-existing risk factor for kidney disease, adding piroxicam (the active ingredient in Suganril-SL) significantly elevates this risk.
Suganril-SL Tablets are contraindicated in patients with impaired kidney function. Prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with kidney damage, including papillary necrosis.
Skin reactions, potentially severe and even life-threatening, are a known side effect of Suganril-SL Tablets. These include exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Serious reactions can develop unexpectedly. Report any skin rash, even a mild one, to your physician and cease taking the medication immediately.
Suganril-SL Tablets are contraindicated during pregnancy. Their use is associated with premature ductus arteriosus closure, potentially resulting in fetal cardiac failure and mortality.
Suganril-SL Tablets are not suitable for patients with active peptic ulcers. This medication has been associated with the development of gastric ulcers and bleeding.
Individuals with asthma may experience heightened sensitivity to non-steroidal anti-inflammatory medications, such as aspirin, potentially triggering severe asthma episodes. Physician consultation is advised prior to commencing treatment with these drugs.
Indeed, Suganril-SL Tablets may induce temporary infertility in some cases. Piroxicam's mode of action can potentially hinder or impede the release of ovarian follicles, a factor linked to reversible infertility among certain women. Seek medical advice prior to commencing treatment with this drug.
Suganril-SL Tablets are contraindicated for concurrent use with diuretics. In certain individuals, Suganril-SL Tablets diminish the sodium-excreting action of furosemide and thiazide diuretics. This effect is believed to result from the suppression of renal prostaglandin production.
Suganril-SL Tablets and lithium are contraindicated. Concurrent use results in increased lithium blood levels and decreased kidney-mediated lithium excretion. This effect stems from the NSAID's suppression of renal prostaglandin production. Physician consultation is mandatory prior to initiating Suganril-SL Tablet treatment.
Concurrent use of Suganril-SL tablets and warfarin is contraindicated due to the heightened risk of hemorrhage. Patients should disclose warfarin use to their physician before taking Suganril-SL. Combined administration necessitates rigorous clinical monitoring.
Gastric ulcer risk rises with the use of medications such as corticosteroids and anticoagulants. Prolonged medication use, alcohol consumption, smoking, and advanced age are additional contributing factors to ulcer development.
Individuals experiencing asthma, urticaria, or another allergic response to aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics before or after coronary artery bypass grafting.
Gastrointestinal upset is possible, and in rare instances, severe gastrointestinal adverse events including ulcers and hemorrhage may occur. Serious dermatological reactions like exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis are also potential side effects, as are liver and kidney dysfunction.
Suganril-SL Tablet
172
MRP 210
18% off